USP16 belongs to a large family of deubiquitinating enzymes, proteases that snip ubiquitin tags off target proteins. Ubiquitination is one of the cell’s principal mechanisms for marking proteins for destruction: when chains of ubiquitin molecules, particularly those linked through their lysine 48 residues, are attached to a protein, the proteasome recognizes the tag and degrades the cargo. Deubiquitinases reverse this process, rescuing proteins from degradation and thereby fine-tuning their abundance. In the new study, the researchers found that USP16 is markedly upregulated in gemcitabine-resistant pancreatic cancer specimens, and that elevated levels of the enzyme correlate with metastatic disease and poor patient prognosis, positioning USP16 as a potential biomarker of aggressive disease.

The functional experiments carried out by the team went beyond correlation. When the researchers silenced USP16 genetically or inhibited it pharmacologically, pancreatic cancer cells lost key malignant behaviors: proliferation slowed, invasive capacity diminished, and, critically, sensitivity to gemcitabine was restored. The same effects were reproduced in animal models, where USP16 suppression curbed tumor progression and re-sensitized tumors to chemotherapy. These results, the authors report, held both in vitro and in vivo, suggesting that USP16 is not merely a passenger mutation or a passive marker of aggressive disease but an active participant in maintaining the resistant phenotype.

The mechanistic heart of the paper lies in metabolism. Cancer cells famously favor glycolysis, the fermentation of glucose into lactate, even in the presence of abundant oxygen, a phenomenon known as the Warburg effect. This metabolic reprogramming supplies rapidly dividing tumors with biosynthetic building blocks and helps them survive environmental stress. The researchers demonstrated that USP16 promotes this glycolytic switch by stabilizing a transcription factor called Far Upstream Element Binding Protein 1, or FUBP1. Biochemical analysis showed that USP16 preferentially removes K48-linked polyubiquitin chains from FUBP1, shielding the protein from proteasomal destruction. With FUBP1 stabilized, pancreatic cancer cells accumulate higher levels of this transcription factor in the nucleus.

FUBP1, in turn, drives transcription of lactate dehydrogenase A, or LDHA, the enzyme that catalyzes the conversion of pyruvate to lactate, the final and defining step of anaerobic glycolysis. By enhancing FUBP1-dependent LDHA expression, USP16 effectively turns up the dial on lactate production, fueling the metabolic state that supports rapid proliferation and chemoresistance. The connection is biologically plausible: high glycolytic flux has been repeatedly linked to drug resistance in solid tumors, partly because glycolytic tumors maintain acidic, hypoxic microenvironments that blunt the efficacy of chemotherapeutic agents and promote survival signaling. The USP16-FUBP1-LDHA axis therefore offers a coherent explanation for how a single deubiquitinase can simultaneously promote metastatic behavior and undermine gemcitabine therapy.

Perhaps the most intricate portion of the study concerns how USP16 itself becomes overexpressed in pancreatic cancer in the first place. The researchers traced the excess USP16 to two upstream layers of regulation. The first involves N6-methyladenosine, or m6A, the most abundant internal chemical modification in messenger RNA. The methyltransferase-like 3 enzyme, METTL3, installs m6A marks on the USP16 transcript, and these modifications enhance the message’s translation or processing. The second layer involves Insulin-like Growth Factor 2 mRNA-Binding Protein 1, or IGF2BP1, a reader protein that recognizes m6A-modified transcripts and stabilizes them, preventing degradation. Together, METTL3-mediated methylation and IGF2BP1-dependent stabilization elevate USP16 protein levels in pancreatic cancer cells, setting the entire pathological cascade in motion.

This architecture, which the authors describe as a METTL3/IGF2BP1-USP16-FUBP1-LDHA regulatory axis, is notable because it links three major themes in contemporary cancer biology: epitranscriptomic regulation through RNA modifications, post-translational control through ubiquitination, and metabolic reprogramming through glycolysis. Each layer of the axis represents a potential point of therapeutic intervention, and the study’s demonstration that both genetic and pharmacological USP16 inhibition suppress tumor progression suggests that deubiquitinase inhibitors could form the basis of new combination strategies designed to be administered alongside gemcitabine.

The clinical implications are considerable. Gemcitabine resistance is one of the chief reasons pancreatic cancer has a five-year survival rate that remains among the lowest of any major cancer. If USP16 levels can be measured reliably in tumor biopsies, the enzyme could serve as a biomarker identifying patients likely to derive limited benefit from gemcitabine-based regimens, guiding clinicians toward alternative or intensified approaches. More ambitiously, if USP16 inhibitors can be developed with acceptable safety profiles, they might resensitize resistant tumors to existing chemotherapy, extending the usefulness of a drug that has been a workhorse in pancreatic oncology for decades. The study’s finding that pharmacological USP16 inhibition restored gemcitabine sensitivity in vivo provides an early proof of concept for that strategy.

Caveats remain, as they do with any preclinical study. The work was conducted in cell lines and animal models, and the translation of deubiquitinase inhibition into human therapy will require medicinal chemistry advances, since deubiquitinases share catalytic mechanisms that can make selective inhibition challenging. The authors also note that the published version is an early-release, peer-reviewed accepted manuscript subject to further editorial refinement. Nonetheless, the identification of a complete signaling axis, from RNA modification through protein stabilization to metabolic enzyme expression, gives researchers a detailed map of a resistance pathway that had remained poorly understood, and it adds USP16 to the growing list of deubiquitinating enzymes implicated in cancer metabolism.

For a disease that has seen painfully slow therapeutic progress, studies that illuminate the machinery of chemoresistance carry real weight. By showing how an m6A-modified, IGF2BP1-stabilized transcript elevates a deubiquitinase that in turn protects a transcription factor governing lactate metabolism, the research team has connected molecular layers that are usually studied in isolation. Whether targeting USP16 will ultimately improve outcomes for patients with pancreatic ductal adenocarcinoma will depend on the development of clinically viable inhibitors and appropriately designed trials, but the study establishes a clear, testable framework for attacking gemcitabine resistance at its metabolic roots, and it underscores how deeply the survival of this formidable cancer depends on the reprogramming of its energy economy.

Subject of Research: USP16-mediated glycolytic reprogramming and gemcitabine resistance in pancreatic ductal adenocarcinoma

Article Title: USP16 promotes pancreatic ductal adenocarcinoma progression and gemcitabine resistance through FUBP1/LDHA axis-mediated glycolysis

Article References: Dong, Y., Lin, C., Fang, H., Tan, Z., Lu, J., Liu, Z., Lai, S., & Wang, Y. (2026). USP16 promotes pancreatic ductal adenocarcinoma progression and gemcitabine resistance through FUBP1/LDHA axis-mediated glycolysis. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06466-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06466-w

Keywords: pancreatic ductal adenocarcinoma, USP16, deubiquitinase, FUBP1, LDHA, glycolysis, gemcitabine resistance, m6A modification, METTL3, IGF2BP1, cancer metabolism, chemoresistance

Long non-coding RNAs, once dismissed as transcriptional noise, are now recognized as powerful regulators of gene expression in cancer. SSTR5-AS1 is an antisense transcript associated with the somatostatin receptor 5 gene locus, and previous work had hinted at its involvement in tumor biology. In the new study, the authors confirmed that SSTR5-AS1 is significantly overexpressed in esophageal cancer samples compared with adjacent healthy tissue, and that high levels of the transcript correlate with poor clinical prognosis. When the researchers measured SSTR5-AS1 in esophageal cancer cell lines, they found the same pattern of enrichment, establishing the RNA as a consistent feature of the malignancy rather than a sporadic artifact of tumor heterogeneity.

To determine what this RNA actually does inside cancer cells, the team performed a series of loss-of-function experiments. When SSTR5-AS1 was knocked down, the cancer cells lost several of their hallmark aggressive behaviors. Proliferation slowed, colony formation in soft agar diminished, and the cells became markedly less capable of migration and invasion, the processes that underpin metastatic spread. These results suggested that SSTR5-AS1 is not a passive bystander in esophageal cancer but an active driver of tumor progression, promoting the phenotypic traits that clinicians fear most.

The most striking discovery, however, concerned how the cells died. Rather than undergoing apoptosis, the conventional form of programmed cell death, SSTR5-AS1-depleted cells displayed the unmistakable biochemical fingerprints of ferroptosis. Levels of lipid reactive oxygen species rose sharply, intracellular ferrous iron accumulated, and malondialdehyde, a canonical marker of lipid peroxidation, increased substantially. At the same time, glutathione, the cell’s principal antioxidant defense, was depleted. When the researchers applied pharmacological inhibitors of ferroptosis, these biochemical changes were reversed and cell survival was restored, confirming that ferroptosis was indeed the mechanism by which SSTR5-AS1 suppression killed the cancer cells.

Ferroptosis has emerged over the past decade as a promising vulnerability in cancer therapy. Because tumor cells often rewire their metabolism to resist apoptosis, inducing ferroptosis offers an alternative route to eliminate them. The new findings place SSTR5-AS1 squarely within this emerging field, identifying it as a brake on ferroptotic death in esophageal cancer. In effect, tumors that overproduce this RNA are better equipped to withstand the oxidative stress that would otherwise destroy their membranes, giving them a decisive survival advantage in the hostile environment of the esophagus.

Having established that SSTR5-AS1 suppresses ferroptosis, the researchers next asked how it exerts this effect at the molecular level. Through RNA-protein interaction analyses, they found that SSTR5-AS1 physically recruits a protein called FAM120A, a factor known to associate with RNA stability complexes. This interaction allows SSTR5-AS1 to stabilize the messenger RNA encoding UHRF1, a well-characterized epigenetic regulator frequently overexpressed in cancers and implicated in maintaining the proliferative state of tumor cells. By protecting UHRF1 mRNA from degradation, the SSTR5-AS1/FAM120A complex keeps UHRF1 protein levels high, which in turn sustains the cellular conditions that prevent ferroptosis from taking hold.

This discovery defines what the authors describe as the SSTR5-AS1/FAM120A/UHRF1 axis, a linear signaling pathway connecting a non-coding RNA to a chromatin-modifying oncogene and ultimately to a specific mode of cell death. The axis provides a coherent mechanistic explanation for the clinical observations: patients whose tumors express high levels of SSTR5-AS1 carry tumors that are simultaneously more invasive and more resistant to ferroptotic elimination. Disrupting any node of this axis, whether by targeting the RNA itself, its protein partner FAM120A, or the downstream UHRF1 message, could theoretically restore the cancer cell’s sensitivity to ferroptosis.

But the story does not end there. The team also investigated what keeps SSTR5-AS1 itself stable and abundant in cancer cells. Their experiments revealed that the RNA is decorated with N6-methyladenosine, or m6A, the most prevalent internal chemical modification found on mammalian messenger and non-coding RNAs. Counterintuitively, rather than marking the transcript for destruction, the m6A marks on SSTR5-AS1 are read by IGF2BP1, an m6A reader protein of the insulin-like growth factor 2 mRNA-binding protein family, which protects the RNA from decay. The methyltransferase METTL3, the principal enzyme that installs m6A marks throughout the transcriptome, was shown to be essential for this process. When METTL3 or IGF2BP1 activity was compromised, SSTR5-AS1 levels fell, and the downstream consequences rippled through the entire axis.

This m6A-dependent stabilization adds a crucial epitranscriptomic layer to the regulatory circuit. It means that the abundance of SSTR5-AS1, and therefore the ferroptosis resistance of esophageal cancer cells, is ultimately controlled by the cell’s RNA modification machinery. The finding aligns with a growing body of evidence that m6A modification acts as a master switch in cancer, influencing everything from stemness and immune evasion to therapy resistance. In this case, the methylation system works in favor of the tumor, ensuring that a pro-survival non-coding RNA remains plentiful precisely where it does the most damage.

The therapeutic implications of the study are considerable. Because SSTR5-AS1 sits upstream of both UHRF1 stabilization and ferroptosis suppression, it represents an attractive target for intervention. Antisense oligonucleotides or small interfering RNAs designed to degrade SSTR5-AS1 could, in principle, strip esophageal cancer cells of their ferroptosis defenses and sensitize them to existing chemoradiotherapy or to emerging ferroptosis-inducing drugs. Alternatively, strategies aimed at blocking the METTL3-IGF2BP1 stabilization of the RNA, or at disrupting the interaction between SSTR5-AS1 and FAM120A, could achieve similar effects at different points in the pathway. The study was supported by the Natural Science Foundation of Hunan Province and approved by the Ethics Committee of the Affiliated Nanhua Hospital, and the authors note that further preclinical validation will be needed before such approaches reach the clinic.

Beyond its immediate relevance to esophageal cancer, the work contributes to a broader conceptual shift in cancer biology. It illustrates how non-coding RNAs, RNA-binding proteins, epigenetic regulators, and RNA chemical modifications can be woven together into a single, coherent circuit that governs a fundamental cell fate decision. Ferroptosis research has largely focused on metabolic enzymes, iron handling, and lipid chemistry; the demonstration that an m6A-modified long non-coding RNA can orchestrate resistance to this death modality expands the field’s mechanistic horizon. As researchers continue to map the epitranscriptomic landscape of tumors, transcripts like SSTR5-AS1 are likely to prove that the most important regulators of cancer survival are not always proteins, and that the dark matter of the genome holds targets worth pursuing.

For patients with esophageal cancer, whose five-year survival rates remain dismally low despite advances in surgery and systemic therapy, the identification of actionable vulnerabilities is urgently needed. The SSTR5-AS1/FAM120A/UHRF1 axis offers a molecularly defined, druggable logic: high SSTR5-AS1 predicts poor outcome, its depletion triggers ferroptotic death, and its stability depends on enzymes and readers that can already be pharmacologically manipulated in laboratory settings. Whether clinical translation follows will depend on the development of safe and effective delivery systems for RNA-targeted therapeutics and on trials that test whether ferroptosis induction can complement existing treatments. For now, the study stands as a compelling example of how basic molecular discovery, pursued at the level of individual RNA transcripts and their chemical marks, can illuminate new paths through one of oncology’s most stubborn challenges.

Subject of Research: m6A-modified long non-coding RNA SSTR5-AS1 regulation of ferroptosis and UHRF1 mRNA stability in esophageal cancer

Article Title: m6A-enriched SSTR5-AS1 regulates ferroptosis through recruiting FAM120A to stabilize UHRF1 mRNA in esophageal cancer

Article References: Zhang, Y., Yan, T., Lin, X., & Wang, M. (2026). m6A-enriched SSTR5-AS1 regulates ferroptosis through recruiting FAM120A to stabilize UHRF1 mRNA in esophageal cancer. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06441-5

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06441-5

Keywords: SSTR5-AS1, esophageal cancer, ferroptosis, m6A modification, METTL3, IGF2BP1, FAM120A, UHRF1, long non-coding RNA, RNA stability, cancer biology, lipid peroxidation